TMF Technology

Learn More Case Studies

TMF Services

Learn More Case Studies

eTMF Quality and Innovation Seminar | 9th November 2017 | Paris, France

Phlexglobal is pleased to invite you to our complimentary eTMF Quality and Innovation Seminar in Paris this November.

We will begin with coffee at 10am followed by an exciting agenda where industry leading TMF experts will address the following:

• An update on the Regulations and how they are affecting the world of TMF
• Building a strong quality culture
• How to execute a TMF quality program and inspection readiness using innovative eTMF oversight tools
• Sponsor case study: Turning negative inspection findings into a positive quality plan
• CRO and Sponsor eTMF collaboration
• CRO eTMFs – you have received them back- what do you do with them now? …and for the next 25 years?
• Panel discussion: Ask our expert panel whatever you want either related to the sessions or burning TMF related questions you would like the answer to
• Live PhlexEview 4.3 demonstration

We are also pleased to announce that we will be joined by a number of keynote speakers including:
Eldin Rammell | Managing Director | Rammell Consulting
Franck Gressier | Head of Clinical Quality Assurance | Pierre Fabre
Emma Webby-Mears | Senior Manager – Clinical Documents | Vectura
Karen Roy | Senior Vice President, Client Solutions | Phlexglobal
Steve Dean | Solutions Consultant | Phlexglobal

A complimentary lunch will be provided.

If you would like to join us for this seminar please register here:

Space is limited. Reserve your place now!

We look forward to meeting you there.

What our customers say about us...

"There are CROs that have the capability to do it, some do have the electronic systems. But there isn’t anybody I know who provides as good a solution as Phlexglobal."
Senior Director in Clinical Operations, top 20 global pharma
"Phlexglobal has experience in handling eTMF documents and has this as its core competency. It makes sense to outsource to them."
Associate Director of MRP Management, US pharma

Back to Top